All In Biotech

NDA 050715 · Novartis

Neoral

Cyclosporine · Oral · Calcineurin Inhibitor Immunosuppressant

Last checked: Nov 20, 2026Latest source record: Sep 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Jul 14, 1995

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,166

250 Phase 3, 65 recruiting

FAERS reports

71,471

65,437 serious, 13,460 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING Only physicians experienced in management of systemic immunosuppressive therapy for the indicated disease should prescribe Neoral. At doses used in solid organ transplantation, only physicians experienced in immunosuppressive therapy and management of organ transplant recipients should prescribe Neoral. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient. Neoral, a systemic immunosuppressant, may increase the susceptibility to infection and the development of neoplasia. In kidney, liver, and heart transplant patients Neoral may be administered with other immunosuppressive agents. Increased susceptibility to infection and the possible development of lymphoma and other...

What it is approved for

From the label in effect Aug 10, 2026.

INDICATIONS AND USAGE Kidney, Liver, and Heart Transplantation Neoral is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Neoral has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Neoral is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Neoral can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Neoral is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with Neoral as with other therapies upon cessation of treatment.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 14, 1995 Original approval · Type 3 - New Dosage Form
3 products under this application
  • NEORAL · CYCLOSPORINE 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CAPSULE, ORAL · Discontinued
  • NEORAL · CYCLOSPORINE 25MG · CAPSULE, ORAL · Prescription · TE AB1
  • NEORAL · CYCLOSPORINE 100MG · CAPSULE, ORAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Cyclosporine" as an intervention, any sponsor and status, largest first.

All 1,166 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective9,115
  • off label use8,353
  • product use in unapproved indication4,122
  • pyrexia3,717
  • pneumonia2,869
  • diarrhoea2,746
  • condition aggravated2,649
  • nausea2,525
  • cytomegalovirus infection2,257
  • fatigue2,098
  • hypertension2,081
  • renal impairment2,032

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,339
20051,287
20061,416
20071,387
20082,313
20092,478
20102,263
20113,028
20122,467
20131,352
20141,556
20151,530
20161,826
20172,279
20182,692
20193,509
20204,673
20214,283
20225,861
20235,833
20247,165
20256,275
20264,647

Recalls

1 FDA enforcement reports for this application.

  • Sep 16, 2022 · Class II · Terminated

    CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Neoral (Cyclosporine, Modified)

2024 spending

$925K

Beneficiaries

264

1,341 claims

Per beneficiary

$3,505

$3.91 per unit

View as table
YearSpending
2020$1,723,632
2021$1,430,503
2022$1,261,029
2023$1,154,941
2024$925,210

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,203 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.